Skip to Content

1,610 Results Found

  • Article
  • Open Access
97 Citations
18,206 Views
11 Pages

Preparation of Silver Nanoparticle and Its Application to the Determination of ct-DNA

  • Chunhua Liu,
  • Xiupei Yang,
  • Hongyan Yuan,
  • Zaide Zhou and
  • Dan Xiao

31 May 2007

A new method to prepare silver nanoparticles was reported in this paper, whichbased on aqueous-gaseous phase reaction of silver nitrate solution and ammonia gas. Theproposed method is effective, rapid, and convenient. Transmission electron microscope...

(This article belongs to the Special Issue Optical Biosensors)
  • Review
  • Open Access
16 Citations
3,704 Views
16 Pages

ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal

  • Sujata Ojha,
  • William Sessions,
  • Yuhang Zhou and
  • Kyaw L. Aung

22 October 2025

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies due to late diagnosis and limited treatment options. Circulating tumor DNA (ctDNA) is a promising, minimally invasive biomarker that could improve the clinical outcomes of p...

(This article belongs to the Section Oncology Biomarkers)
  • Review
  • Open Access
91 Citations
13,494 Views
14 Pages

Role of ctDNA in Breast Cancer

  • Marta Sant,
  • Adrià Bernat-Peguera,
  • Eudald Felip and
  • Mireia Margelí

9 January 2022

Breast cancer is currently classified by immunohistochemistry. However, technological advances in the detection of circulating tumor DNA (ctDNA) have made new options available for diagnosis, classification, biological knowledge, and treatment select...

(This article belongs to the Special Issue Feature Paper from Journal Reviewers)
  • Review
  • Open Access
49 Citations
6,190 Views
20 Pages

The Role of ctDNA in Gastric Cancer

  • Justin Mencel,
  • Susanna Slater,
  • Elizabeth Cartwright and
  • Naureen Starling

18 October 2022

Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making...

(This article belongs to the Special Issue Contemporary Perspectives and Emerging Trends in the Management of Gastric Cancer)
  • Review
  • Open Access
114 Citations
13,833 Views
12 Pages

Liquid Biopsy, ctDNA Diagnosis through NGS

  • Chen Lin,
  • Xuzhu Liu,
  • Bingyi Zheng,
  • Rongqin Ke and
  • Chi-Meng Tzeng

28 August 2021

Liquid biopsy with circulating tumor DNA (ctDNA) profiling by next-generation sequencing holds great promise to revolutionize clinical oncology. It relies on the basis that ctDNA represents the real-time status of the tumor genome which contains info...

(This article belongs to the Special Issue The Increasing Role of Next Generation Sequencing Methods in Mutation Analysis)
  • Review
  • Open Access
4 Citations
3,123 Views
6 Pages

19 July 2023

Circulating tumor DNA (ctDNA) has been investigated as a potential noninvasive biomarker for disease prognostication, monitoring, and treatment selection in various tumor types, including renal cell carcinoma (RCC). In this narrative review, we explo...

  • Review
  • Open Access
14 Citations
5,103 Views
26 Pages

State of the Art: ctDNA in Upper Gastrointestinal Malignancies

  • Ibone Labiano,
  • Ana Elsa Huerta,
  • Virginia Arrazubi,
  • Irene Hernandez-Garcia and ,
  • Elena Mata,
  • David Gomez,
  • Hugo Arasanz,
  • Ruth Vera and
  • Maria Alsina
  • + 4 authors+ 0 author

21 February 2023

Circulating tumor DNA (ctDNA) has emerged as a promising non-invasive source to characterize genetic alterations related to the tumor. Upper gastrointestinal cancers, including gastroesophageal adenocarcinoma (GEC), biliary tract cancer (BTC) and pan...

(This article belongs to the Special Issue Emerging Therapies in the Management of Gastrointestinal Malignancies)
  • Article
  • Open Access
6 Citations
3,832 Views
15 Pages

Quantitative ctDNA Detection in Hepatoblastoma: Implications for Precision Medicine

  • Smadar Kahana-Edwin,
  • James Torpy,
  • Lucy E. Cain,
  • Anna Mullins and ,
  • Geoffrey McCowage,
  • Sarah E. Woodfield,
  • Sanjeev A. Vasudevan,
  • Dan P. T. Shea,
  • Andre E. Minoche and
  • Jonathan Karpelowsky
  • + 8 authors+ 3 authors

19 December 2023

Hepatoblastoma is characterized by driver mutations in CTNNB1, making it an attractive biomarker for a liquid biopsy approach utilizing circulating tumor DNA (ctDNA). This prospective observational study sought to ascertain the feasibility of ctDNA d...

(This article belongs to the Special Issue Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers)
  • Review
  • Open Access
6 Citations
2,705 Views
19 Pages

18 November 2025

The role of circulating tumor DNA (ctDNA) in gastroesophageal adenocarcinoma (GEA) has expanded in recent years. In resectable disease, postoperative ctDNA is able to detect patients at highest risk of recurrence months before scans. Tumor-informed a...

(This article belongs to the Special Issue Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers (2nd Edition))
  • Review
  • Open Access
17 Citations
3,702 Views
13 Pages

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal

  • Edina Dizdarevic,
  • Torben Frøstrup Hansen and
  • Anders Jakobsen

30 April 2022

The treatment of locally advanced rectal cancer (LARC) has evolved during the last decades, but recurrence remains a problem. Circulating tumor DNA (ctDNA) may result in an individualized treatment approach with improved survival and quality of life,...

(This article belongs to the Special Issue A Model for Improved Care of Patients with Colorectal Cancer – Experience from a Center of Clinical Excellence)
  • Review
  • Open Access
9 Citations
8,980 Views
16 Pages

Clinical Utility of ctDNA Analysis in Lung Cancer—A Review

  • Kamil Makar,
  • Agata Wróbel,
  • Adam Antczak and
  • Damian Tworek

Circulating free DNA (cfDNA) is genetic material released from various cells into bodily fluids. Among its fractions, circulating tumor DNA (ctDNA) originates from tumor cells and reflects their genetic material, including mutations and epigenetic ch...

  • Review
  • Open Access
10 Citations
3,625 Views
13 Pages

Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review

  • Hugo C. Temperley,
  • Timothy Fannon,
  • Niall J. O’Sullivan,
  • Maeve O’Neill and ,
  • Benjamin M. Mac Curtain,
  • Charles Gilham,
  • Jacintha O’Sullivan,
  • Grainne O’Kane,
  • Brian J. Mehigan and
  • Michael E. Kelly
  • + 9 authors+ 4 authors

This systematic review investigates the potential of circulating tumour DNA (ctDNA) as a predictive biomarker in the management and prognosis of squamous cell carcinoma of the anal canal (SCCA). PubMed, EMBASE, and Cochrane Central Registry of Contro...

(This article belongs to the Special Issue Molecular Mechanisms and Therapies of Colorectal Cancer 3.0)
  • Review
  • Open Access
1,340 Views
15 Pages

Using ctDNA to Inform Adjuvant Therapy for Urologic Malignancies

  • Rajvi Goradia,
  • Taylor Goodstein,
  • Debasish Sundi,
  • Akshay Sood and ,
  • Shawn Dason and
  • Eric A. Singer
  • + 1 author+ 0 author

31 March 2026

Decisions regarding the use of adjuvant systemic therapy in genitourinary (GU) malignancies—including bladder, kidney, and prostate cancers—are currently driven by clinicopathologic risk factors, which incompletely capture individual risk...

(This article belongs to the Special Issue Clinical Trials and Evolving Treatment Paradigms in Urologic Cancers)
  • Review
  • Open Access
15 Citations
5,300 Views
24 Pages

The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology

  • Keren Rouvinov,
  • Rashad Naamneh,
  • Alexander Yakobson,
  • Wenad Najjar and ,
  • Mahmoud Abu Amna,
  • Arina Soklakova,
  • Ez El Din Abu Zeid,
  • Ronen Brenner,
  • Mohnnad Asla and
  • Walid Shalata
  • + 8 authors+ 3 authors

Background: Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), represents a significant advancement in oncology. Unlike traditional tissue biopsies, ctDNA offers a minimally invasive, real-time approach to cancer manag...

(This article belongs to the Special Issue Utilization of Liquid Biopsy in Cancer Diagnosis and Management 2025–2026)
  • Review
  • Open Access
100 Citations
16,084 Views
28 Pages

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation

  • Jonathan Dao,
  • Patrick J. Conway,
  • Baskaran Subramani,
  • Devi Meyyappan and ,
  • Sammy Russell and
  • Daruka Mahadevan
  • + 1 author+ 0 author

25 August 2023

The detection of circulating tumor DNA (ctDNA) in liquid biopsy samples as an oncological marker is being used in clinical trials at every step of clinical management. As ctDNA-based liquid biopsy kits are developed and used in clinics, companies wor...

(This article belongs to the Special Issue Liquid Biopsy in Cancers)
  • Article
  • Open Access
6 Citations
3,042 Views
10 Pages

Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management

  • Britney Niemann,
  • John Moise,
  • Michael Sestito,
  • Midhun Malla and ,
  • Kevin Train,
  • Douglas Murken,
  • Keri Mayers,
  • Emily Groves and
  • Mary Garland-Kledzik
  • + 4 authors+ 0 author

14 March 2024

Background: Circulating tumor DNA (ctDNA) is extracellular DNA released by tumors and has been proposed as a marker of residual disease as well as a predictor of disease recurrence in the adjuvant setting. However, data are lacking on the utility of...

(This article belongs to the Special Issue Recent Updates on Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery)
  • Article
  • Open Access
504 Views
13 Pages

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma

  • Alyssa K. Steimle,
  • Amir M. Forati,
  • Alice Y. Zhou,
  • Trevor McCracken and ,
  • Meena M. Hosny,
  • Golbarg Rahimi,
  • Janmesh D. Patel,
  • Caroline Burkey,
  • Jessica Caraway and
  • Vincent T. Ma
  • + 17 authors+ 12 authors

18 September 2026

Background/Objectives: ctDNA is evolving as an important biomarker for prognostic assessment in advanced melanoma. However, the utility of ctDNA monitoring during concurrent ICI with RT remains incompletely explored. Methods: In this multicenter retr...

(This article belongs to the Special Issue Melanoma Combination Therapy: New Horizons, Challenges and Clinical Breakthroughs)
  • Viewpoint
  • Open Access
1 Citations
513 Views
10 Pages

Small Is Beautiful: Is ctDNA Ready for Routine Implementation in Cancer Management?

  • Caroline Bailleux,
  • Jean-Marc Ferrero,
  • Rym Bouriga,
  • Loic Trapani and ,
  • Baharia Mograbi,
  • Jocelyn Gal and
  • Gérard Milano
  • + 2 authors+ 0 author

23 June 2026

Circulating tumor DNA (ctDNA) has emerged as a transformative tool in cancer diagnostics, enabling the non-invasive detection of tumor-derived DNA fragments released into the bloodstream through cellular lysis or active secretion. ctDNA measurement h...

(This article belongs to the Section Cancer Biomarkers)
  • Review
  • Open Access
46 Citations
8,401 Views
18 Pages

29 September 2020

The current standard treatment for patients with early-stage colon cancer consists of surgical resection, followed by adjuvant therapy in a select group of patients deemed at risk of cancer recurrence. The decision to administer adjuvant therapy, int...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
7 Citations
2,908 Views
12 Pages

Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas

  • David Braig,
  • Alexander Runkel,
  • Anja E. Eisenhardt,
  • Adrian Schmid and ,
  • Johannes Zeller,
  • Thomas Pauli,
  • Ute Lausch,
  • Julius Wehrle,
  • Peter Bronsert and
  • Steffen U. Eisenhardt
  • + 8 authors+ 3 authors

6 September 2022

Soft tissue sarcomas (STS) are rare tumors of mesenchymal origin with high mortality. After curative resection, about one third of patients suffer from distant metastases. Tumor follow-up only covers a portion of recurrences and is associated with hi...

(This article belongs to the Special Issue Bone and Soft Tissue Sarcomas - Basic Research and Multimodal Treatment Concepts)
  • Systematic Review
  • Open Access
1 Citations
1,798 Views
14 Pages

Clinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review

  • Monika Wojarska,
  • Klaudia Kokot,
  • Paulina Bernecka,
  • Aleksandra Kierczak and ,
  • Natalia Sitkiewicz,
  • Aleksandra Wakszyńska,
  • Tomasz Wichowski,
  • Weronika Skok,
  • Milena Matwiejczuk and
  • Jerzy Jankau
  • + 6 authors+ 1 author

28 February 2026

Background and Objectives: Melanoma is an aggressive cutaneous malignancy with a high recurrence rate even after complete resection. Circulating tumour DNA (ctDNA) has emerged as a promising biomarker for detecting minimal residual disease (MRD), ass...

(This article belongs to the Section Dermatology)
  • Article
  • Open Access
5 Citations
2,147 Views
10 Pages

Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series

  • Eric Rios-Doria,
  • Jonathan B. Reichel,
  • Marc R. Radke,
  • Enna Manhardt and ,
  • Mayumi Rubin-Saika,
  • Christina Lockwood,
  • Elizabeth M. Swisher and
  • Kalyan Banda
  • + 3 authors+ 0 author

21 October 2025

Recurrent ovarian cancer (OC) is challenging to detect early using current methods like CA-125 and imaging. Circulating tumor DNA (ctDNA) may improve disease monitoring. Here, we assess the real-world clinical utility of serial ctDNA analyses in pati...

(This article belongs to the Section Gynecologic Oncology)
  • Article
  • Open Access
9 Citations
3,573 Views
11 Pages

ACEK Biosensor for the Minute-Scale Quantification of Breast Cancer ctDNA

  • Ke Wang,
  • Xiaogang Lin,
  • Maoxiao Zhang,
  • Mengjie Yang and ,
  • Xiang Shi,
  • Mingna Xie and
  • Yang Luo
  • + 2 authors+ 0 author

15 January 2024

Circulating tumor DNA (ctDNA) appears as a valuable liquid biopsy biomarker in the early diagnosis, treatment, and prognosis of cancer. Here, a biosensing method derived from the AC electrokinetics (ACEK) effect was constructed in this study for the...

(This article belongs to the Special Issue Biosensors for Diagnostic Applications)
  • Article
  • Open Access
13 Citations
2,427 Views
17 Pages

Harnessing Plasma Biomarkers to Predict Immunotherapy Outcomes in Hepatocellular Carcinoma: The Role of cfDNA, ctDNA, and Cytokines

  • Elena Vargas-Accarino,
  • Mónica Higuera,
  • María Bermúdez-Ramos,
  • Agnès Soriano-Varela and ,
  • María Torrens,
  • Mònica Pons,
  • Ana María Aransay,
  • José Ezequiel Martín,
  • Francisco Rodríguez-Frías and
  • Beatriz Mínguez
  • + 6 authors+ 1 author

Immunotherapy has improved survival in patients with advanced hepatocellular carcinoma (HCC); yet, objective radiological responses occur in only about 20% of cases, suggesting variable benefits. This study aimed to identify serologic markers predict...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
2 Citations
1,066 Views
11 Pages

Pan-Cancer Pre-Treatment ctDNA Detection Using a Highly Sensitive Tumor-Informed Assay

  • Scott Strum,
  • Clodagh Murray,
  • Sofia Genta,
  • Enrique Sanz-Garcia and ,
  • Albiruni Razak,
  • Stephanie Lheureux,
  • Christodoulos Pipinikas,
  • Ben X. Wang,
  • Amber Chevalier and
  • David W. Cescon
  • + 9 authors+ 4 authors

Circulating tumor DNA (ctDNA) has many potential applications in the management of cancer, including detection, monitoring, and treatment response assessment. This study evaluates pre-treatment ctDNA detection in a single-institution pan-cancer cohor...

(This article belongs to the Special Issue Novel Biomarkers and Emerging Therapeutic Targets for Breast and Gynecologic Cancers)
  • Article
  • Open Access
4 Citations
1,864 Views
13 Pages

Lung Cancer with Isolated Pleural Dissemination as a Potential ctDNA Non-Shedding Tumor Type

  • Huizhao Hong,
  • Yingqian Zhang,
  • Mengmeng Song,
  • Xuan Gao and ,
  • Wenfang Tang,
  • Hongji Li,
  • Shirong Cui,
  • Song Dong,
  • Yilong Wu and
  • Jiatao Zhang
  • + 6 authors+ 1 author

30 July 2025

Objectives: Circulating tumor DNA (ctDNA) has emerged as a reliable prognostic biomarker in both early- and late-stage non-small cell lung cancer (NSCLC) patients. However, its role in NSCLC with pleural dissemination (M1a), a subset of disease with...

(This article belongs to the Section Cancer Metastasis)
  • Systematic Review
  • Open Access
16 Citations
5,413 Views
12 Pages

Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions

  • Rugile Pikturniene,
  • Alvydas Cesas,
  • Sonata Jarmalaite,
  • Arturas Razbadauskas and
  • Vincas Urbonas

18 March 2024

Cutaneous melanoma, an aggressive malignancy, has undergone significant transformation in clinical management with the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies. Current monitoring methods, such as imaging scans, pres...

(This article belongs to the Section Molecular Cancer Biology)
  • Article
  • Open Access
2 Citations
1,105 Views
12 Pages

Feasibility of TP53-Mutated ctDNA Monitoring in High-Grade Endometrial Cancer Using Routine NGS

  • Regine Marlin,
  • Mehdi Jean-Laurent,
  • Clarisse Joachim,
  • Alexis Vallard and ,
  • Sabrina Pennont,
  • Valerie Suez-Panama,
  • Mickaelle Rose,
  • Sylviane Ulric-Gervaise,
  • Sylvie Lusbec and
  • Coralie Ebring
  • + 7 authors+ 2 authors

28 March 2026

Background/Objectives: High-grade endometrial cancer (EC) is associated with poor outcomes, particularly in populations with a high burden of aggressive histologies. There is a critical need for accessible biomarkers to improve prognostic assessment...

(This article belongs to the Section Cancer Biomarkers)
  • Review
  • Open Access
36 Citations
13,301 Views
14 Pages

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer

  • Aakash Desai,
  • Tadana A. Vázquez,
  • Keishla M. Arce,
  • Marcelo Corassa and ,
  • Philip C. Mack,
  • Jhanelle E. Gray and
  • Bruna Pellini
  • + 2 authors+ 0 author

26 February 2024

Circulating tumor DNA (ctDNA) offers a new paradigm in optimizing treatment strategies for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Its potential spans early-stage disease, influencing adjuvant therapy, to ad...

(This article belongs to the Special Issue Liquid Biopsy for Lung Cancer Treatment)
  • Review
  • Open Access
60 Citations
12,546 Views
22 Pages

19 January 2021

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. While there have been significant developments in the treatments for patients with metastatic CRC in recent years, improving outcomes in the adjuvant setting has...

(This article belongs to the Special Issue Adjuvant Chemotherapy for Colorectal Cancer)
  • Article
  • Open Access
25 Citations
4,174 Views
11 Pages

Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma: Association with Metabolic Tumor Burden Determined with FDG-PET/CT

  • Antti Silvoniemi,
  • Jukka Laine,
  • Katri Aro,
  • Linda Nissi and ,
  • Leif Bäck,
  • Jukka Schildt,
  • Jussi Hirvonen,
  • Jaana Hagström,
  • Heikki Irjala and
  • Heikki Minn
  • + 7 authors+ 2 authors

4 August 2023

Background: The detection of circulating tumor DNA (ctDNA) with next-generation sequencing (NGS) in venous blood is a promising tool for the genomic profiling of head and neck squamous cell carcinoma (HNSCC). The association between ctDNA findings an...

(This article belongs to the Section Cancer Biomarkers)
  • Review
  • Open Access
12 Citations
4,690 Views
10 Pages

How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks

  • Estelle Bourbon,
  • Vincent Alcazer,
  • Estelle Cheli,
  • Sarah Huet and
  • Pierre Sujobert

The analysis of circulating tumor DNA (ctDNA) released by tumor cells holds great promise for patients with lymphoma, to refine the diagnostic procedure, clarify the prognosis, monitor the response to treatment, and detect relapses earlier. One of th...

(This article belongs to the Section Biopharmaceuticals)
  • Article
  • Open Access
1 Citations
2,099 Views
11 Pages

Basic ctDNA Panel Promises Affordable Clinical Validity in Colon Cancer Patients but Not in Pancreas Cancer Patients

  • Mandy Radefeldt,
  • Silke Stellmacher-Kaiser,
  • Susann Krake,
  • Brigitte Kragl and ,
  • Sabrina Lemke,
  • Christian Beetz,
  • Peter Bauer,
  • Christian Junghanß and
  • Ruslan Al-Ali
  • + 4 authors+ 0 author

28 November 2023

The potential of circulating tumor DNA (ctDNA) as a biomarker to assess the progression of various solid tumors has been explored extensively. In this study, we investigated the feasibility of utilizing a ctDNA sequencing panel specifically designed...

(This article belongs to the Section Medical Research)
  • Review
  • Open Access
500 Views
28 Pages

Circulating Tumor DNA (ctDNA) for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRC): Current Evidence, Clinical Applications, and Future Directions

  • Hannah Hyde,
  • Emma Mageau,
  • Chelsea M. Leduc,
  • Mitul J. Madhu and ,
  • Noah Dickinson,
  • Tafheem-Un Nisa,
  • Karolina M. Czajka,
  • Stacey A. Santi,
  • Prashant Jani and
  • Sujeenthar Tharmalingam
  • + 6 authors+ 1 author

Minimal residual disease (MRD) is a major contributor to colorectal cancer (CRC) recurrence following curative-intent treatment, yet conventional surveillance methods may fail to detect residual disease at its earliest stages. Circulating tumor DNA (...

(This article belongs to the Topic Cancer Genomics: Emerging Trends and Technological Advances)
  • Article
  • Open Access
24 Citations
5,983 Views
14 Pages

TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer

  • Akiko Arimura,
  • Kazuko Sakai,
  • Kazuhisa Kaneshiro,
  • Takafumi Morisaki and ,
  • Saori Hayashi,
  • Kimihisa Mizoguchi,
  • Mai Yamada,
  • Masaya Kai,
  • Mayumi Ono and
  • Makoto Kubo
  • + 7 authors+ 2 authors

18 March 2024

Precise biomarkers for predicting the therapeutic efficacy of molecularly targeted drugs are limited at the protein level; thus, it has been important to broadly scrutinize individual cancer driver gene mutations for effective cancer treatments. Mult...

(This article belongs to the Special Issue Liquid Biopsy in Cancer 2.0)
  • Article
  • Open Access
7 Citations
3,089 Views
9 Pages

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice

  • Angela Lamarca,
  • Melissa Frizziero,
  • Jorge Barriuso,
  • Zainul Kapacee and ,
  • Wasat Mansoor,
  • Mairéad G. McNamara,
  • Richard A. Hubner and
  • Juan W. Valle
  • + 3 authors+ 0 author

17 February 2022

Background: The role of tumour genomic profiling in the clinical management of well-differentiated neuroendocrine tumours (WdNETs) is unclear. Circulating tumour DNA (ctDNA) may be a useful surrogate for tumour tissue when the latter is insufficient...

(This article belongs to the Special Issue Endocrine and Neuroendocrine Cancers)
  • Article
  • Open Access
2 Citations
3,947 Views
12 Pages

Evaluating Liquid Biopsy for Circulating Tumor DNA (ctDNA) Detection as a Complementary Diagnostic Tool in Thyroid Cancer Among Ecuadorian Women

  • Santiago Cadena-Ullauri,
  • Viviana A. Ruiz-Pozo,
  • Elius Paz-Cruz,
  • Rafael Tamayo-Trujillo and ,
  • Patricia Guevara-Ramírez,
  • Oscar Jaramillo-Calvas,
  • Cristhian García,
  • Mikaela García,
  • Ana Pérez and
  • Ana Karina Zambrano
  • + 9 authors+ 4 authors

Thyroid cancer (TC) is the most common endocrine malignancy, with a rising global incidence. In Ecuador, TC rates are among the highest worldwide. Generally, fine-needle aspiration (FNA) remains the standard diagnostic tool; however, due to its limit...

(This article belongs to the Section Molecular Biology)
  • Article
  • Open Access
8 Citations
3,076 Views
15 Pages

ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer

  • Valentina Glueck,
  • Christoph Grimm,
  • Magdalena Postl,
  • Christian Brueffer and ,
  • Nuria Segui,
  • Miguel Alcaide,
  • Lucia Oton,
  • Yilun Chen,
  • Lao H. Saal and
  • Leonhard Muellauer
  • + 7 authors+ 2 authors

25 February 2025

Background/Objectives: The surgeon’s subjective intraoperative evaluation is the standard of care to assess postoperative residual disease (RD) in advanced epithelial ovarian cancer (EOC). We investigated the feasibility of ctDNA as an objectiv...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
12 Citations
3,548 Views
9 Pages

The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma

  • Paweł Sobczuk,
  • Katarzyna Kozak,
  • Sylwia Kopeć,
  • Paweł Rogala and ,
  • Tomasz Świtaj,
  • Hanna Koseła-Paterczyk,
  • Aleksandra Gos,
  • Andrzej Tysarowski and
  • Piotr Rutkowski
  • + 4 authors+ 0 author

2 February 2022

Assessment of BRAF mutation status is mandatory in advanced, treatment-naïve melanoma patients. Liquid biopsy can be an alternative in cases with inadequate or unavailable tumor tissue. The aim of our study was to evaluate the clinical utility o...

(This article belongs to the Special Issue Biomarkers in Melanoma Patients)
  • Review
  • Open Access
24 Citations
6,339 Views
25 Pages

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review

  • Wenwen Wang,
  • Zhiyao Zheng and
  • Jianyong Lei

6 September 2023

Thyroid cancer has become more common in recent years all around the world. Many issues still need to be urgently addressed in the diagnosis, treatment, and prognosis of thyroid cancer. Liquid biopsy (mainly circulating tumor DNA (ctDNA), circulating...

(This article belongs to the Special Issue Liquid Biopsy in Cancers)
  • Article
  • Open Access
2 Citations
2,245 Views
13 Pages

14 May 2025

Background/Aims: Circulating tumor DNA (ctDNA) is becoming a valuable cancer biomarker for clinical decision-making. Nevertheless, the lack of quality control materials to assess the reliability of test results remains a challenge. This study aimed t...

(This article belongs to the Section Human Genomics and Genetic Diseases)
  • Hypothesis
  • Open Access
10 Citations
3,347 Views
14 Pages

Circulating Tumor DNA (ctDNA) Dynamics Predict Early Response to Treatment in Metastasized Gastroesophageal Cancer (mGEC) After 2 Weeks of Systemic Treatment

  • Stefan Tatalovic,
  • Bernhard Doleschal,
  • Alexander Kupferthaler,
  • Stephan Grundner and ,
  • Jonathan Burghofer,
  • Gerald Webersinke,
  • Simon Schwendinger,
  • Emina Jukic,
  • Johannes Zschocke and
  • Patrick Kirchweger
  • + 12 authors+ 7 authors

26 November 2024

mGEC is associated with poor overall survival (OS) of approximately 4–10 months. CtDNA is emerging as a promising prognostic biomarker with high potential for early relapse detection. However, until now, there was little knowledge on serial ctD...

(This article belongs to the Special Issue Liquid Biopsy in Cancer 2.0)
  • Article
  • Open Access
18 Citations
3,784 Views
14 Pages

Evaluation of ctDNA in the Prediction of Response to Neoadjuvant Therapy and Prognosis in Locally Advanced Rectal Cancer Patients: A Prospective Study

  • Marina Morais,
  • Telma Fonseca,
  • Diogo Melo-Pinto,
  • Isabel Prieto and ,
  • Ana Teresa Vilares,
  • Ana Luísa Duarte,
  • Patrícia Leitão,
  • Luís Cirnes,
  • José Carlos Machado and
  • Silvestre Carneiro
  • + 5 authors+ 0 author

10 March 2023

“Watch and wait” is becoming a common treatment option for patients with locally advanced rectal cancer (LARC) submitted to neoadjuvant treatment. However, currently, no clinical modality has an acceptable accuracy for predicting patholog...

(This article belongs to the Section Medicinal Chemistry)
  • Systematic Review
  • Open Access
23 Citations
4,895 Views
18 Pages

Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis

  • Farzana Y. Zaman,
  • Ashwin Subramaniam,
  • Afsana Afroz,
  • Zarka Samoon and ,
  • Daniel Gough,
  • Surein Arulananda and
  • Muhammad Alamgeer
  • + 2 authors+ 0 author

23 April 2023

Background: Liquid biopsy (LB) analysis using (ctDNA)/cell-free DNA (cfDNA) is an emerging alternative to tissue profiling in (NSCLC). LB is used to guide treatment decisions, detect resistance mechanisms, and predicts responses, and, therefore, outc...

(This article belongs to the Special Issue Liquid Biopsy for Lung Cancer Treatment)
  • Review
  • Open Access
36 Citations
5,564 Views
16 Pages

The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review

  • Agnieszka Kopystecka,
  • Rafał Patryn,
  • Magdalena Leśniewska,
  • Julia Budzyńska and
  • Ilona Kozioł

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is one of the leading causes of cancer-related deaths worldwide. Despite advances in medicine, it is still a cancer with a very poor prognosis. Both imaging and liver biopsy s...

(This article belongs to the Special Issue Advanced Research on Biomarkers in Gastrointestinal Cancer)
  • Commentary
  • Open Access
17 Citations
3,811 Views
8 Pages

Real-World Technical Hurdles of ctDNA NGS Analysis: Lessons from Clinical Implementation

  • Simon Cabello-Aguilar,
  • Julie A. Vendrell and
  • Jérôme Solassol

23 September 2025

Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) represents a minimally invasive alternative to conventional tissue biopsies, providing real-time genomic snapshots of heterogeneous tumors from blood draws. This liquid biopsy approach...

  • Review
  • Open Access
65 Citations
8,963 Views
14 Pages

14 November 2021

The ability to detect minimal residual disease (MRD) after a curative-intent surgery or treatment is of paramount importance, because it offers the possibility to help guide the clinical decisions related adjuvant therapy. Thus, the earlier MRD is de...

(This article belongs to the Special Issue Liquid Nucleic Acid-Based Biomarkers in Solid Tumors)
  • Review
  • Open Access
2 Citations
2,086 Views
32 Pages

The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis

  • Andrea C. Kakouri,
  • Maria Spiliotaki,
  • Constantinos Deltas,
  • Gregory Papagregoriou and
  • Haris Charalambous

Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) have emerged as promising non-invasive biomarkers for the immunotherapy response in advanced non-small cell lung cancer (NSCLC). However, their clinical utility remains uncertain due...

(This article belongs to the Special Issue State-of-the-Art Immunotherapy for Non-Small-Cell Lung Cancer)
  • Article
  • Open Access
10 Citations
3,643 Views
16 Pages

Molecular Profiling of Endocrine Resistance in HR+/HER2-Metastatic Breast Cancer: Insights from Extracellular Vesicles-Derived DNA and ctDNA in Liquid Biopsies

  • Ana Martínez-Rodríguez,
  • Jesús Fuentes-Antrás,
  • Víctor Lorca,
  • Alfonso López de Sá and ,
  • Pedro Pérez-Segura,
  • Fernando Moreno,
  • Jose Angel García-Sáenz and
  • Vanesa García-Barberán
  • + 3 authors+ 0 author

4 December 2024

Standard treatments in hormone receptor-positive (HR+)/HER2-metastatic breast cancer (mBC) typically involve endocrine therapy (ET) combined with CDK4/6 inhibitors, yet resistance to ET remains a persistent challenge in advanced cases. A deeper knowl...

(This article belongs to the Special Issue Breast Cancer, Metastatic Breast Cancer, Therapeutic Approaches, 2nd Edition)
  • Review
  • Open Access
16 Citations
8,378 Views
20 Pages

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era

  • Jacopo Costa,
  • Alexandro Membrino,
  • Carol Zanchetta,
  • Simona Rizzato and ,
  • Francesco Cortiula,
  • Ciro Rossetto,
  • Giacomo Pelizzari,
  • Giuseppe Aprile and
  • Marianna Macerelli
  • + 4 authors+ 0 author

20 December 2024

Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing (NGS)...

(This article belongs to the Section Molecular Oncology)

of 33